Stockscreener 앱 받기
829.43
0.07%
0.59
시간 외 거래:
829.44
0.01
+0.00%
Regeneron Pharmaceuticals Inc 주식(REGN)의 최신 뉴스
Regeneron Pharmaceuticals exec sells shares worth $844,610 - Investing.com
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Central Bank & Trust Co. Acquires 650 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
StockNews.com Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy - MarketBeat
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Benzinga
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors - Business Wire
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
TD Cowen maintains Buy on Regeneron shares, sees growth in Eylea HD - Investing.com
Regeneron Pharmaceuticals reports new FKBP1A ligands - BioWorld Online
Van ECK Associates Corp Acquires 4,742 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
A Decade On, How Deep Do Regeneron’s Oncology Foundations Go? - Citeline
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom - MSN
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade) (NASDAQ:REGN) - Seeking Alpha
4,785 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Empire Life Investments Inc. - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Regeneron price target lowered to $1,126 from $1,137 at Truist - Yahoo Finance
BMO cuts Regeneron target on Eylea HD miss, competition concerns By Investing.com - Investing.com Australia
AMGN: 3 Biotechnology Stocks With Promising Pipelines - StockNews.com
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors - Business Wire
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Trimmed by New York State Common Retirement Fund - MarketBeat
BMO cuts Regeneron target on Eylea HD miss, competition concerns - Investing.com
What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity? - Insider Monkey
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,195.00 by Analysts at Piper Sandler - MarketBeat
Analyst recommendations: Amazon.com, Mastercard, Bristol-Myers Squibb Company, Uber Technologies, Regeneron Pharmaceuticals... - Marketscreener.com
Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure - BioSpace
Regeneron Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Regeneron: Investors In Panic Mode On Increased Eylea Fears (NASDAQ:REGN) - Seeking Alpha
Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Q3 2024 Regeneron Pharmaceuticals Inc Earnings Call - AOL
Regeneron Pharmaceuticals Inc (REGN) Q3 2024 Earnings Call Highl - GuruFocus.com
Regeneron: Q3 Earnings Snapshot - The Advocate
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight - Yahoo Finance
Regeneron Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Regeneron Shares Drop After Sales of Higher-Dose Eylea Miss Expectations - MarketWatch
Regeneron Pharmaceuticals Files For Mixed Shelf - XM
Evercore ISI cuts Regeneron target to $1,170 from $1,175 - Investing.com India
Evercore ISI cuts Regeneron target to $1,170 from $1,175 By Investing.com - Investing.com UK
Regeneron Earnings Top Views For Biotech Giant - MSN
Eylea headwinds said to be behind Regeneron’s post-Q3 plunge - MSN
Earnings call: Regeneron reports robust Q3 growth, Dupixent shines By Investing.com - Investing.com Canada
Earnings call: Regeneron reports robust Q3 growth, Dupixent shines - Investing.com
Regeneron stock falls on Eylea headwinds (REGN:NASDAQ) - Seeking Alpha
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? - Yahoo Finance
Regeneron Pharmaceuticals Down Nearly 10%, on Track for Largest Percent Decrease Since March 2020 — Data Talk - Morningstar
Regeneron's Eylea HD makes progress but doesn't dent the momentum of Roche's Vabysmo - FiercePharma
Regeneron shares drop as higher-dose Eylea drug misses sales estimates - Reuters
Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter
Regeneron down 10% despite top and bottom line beats - MSN
Regeneron: Adjusted EPS& up 8% in Q3 - Marketscreener.com
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales - Yahoo Finance
Regeneron Pharmaceuticals Q3 2024 Earnings: EPS Soars to $11.54, - GuruFocus.com
Oak Harvest Investment Services Purchases 567 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron beats results estimates on demand for eczema treatment, eye drug - Marketscreener.com
Regeneron Q3 earnings top estimates, revenue up 11% YoY - Investing.com
Regeneron Reports Third Quarter 2024 Financial and Operating Results - The Manila Times
5.73%
1.73%
자본화:
|
볼륨(24시간):